Passwort vergessen?
Werden Sie kostenlos Mitglied
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Dynamische Kurse 
  1. Startseite
  2. Aktien
  3. Schweiz
  4. Swiss Exchange
  5. PolyPeptide Group AG
  6. News
  7. Übersicht
    PPGN   CH1110760852


ÜbersichtAlle NewsAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News

EQS-Adhoc: PolyPeptide Group gibt vollständige -2-

05.05.2021 | 17:43
(the "MiFID II Target Market Assessment"). 
Solely for the purposes of the product governance requirements of Chapter 3 of the FCA Handbook Product Intervention 
and Product Governance Sourcebook (the "UK Product Governance Requirements"), and /or any equivalent requirements 
elsewhere, and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any 
"manufacturer" (for the purposes of the UK Product Governance Requirements and/or any equivalent requirements 
elsewhere) may otherwise have with respect thereto, the Securities have been subject to a product approval process by 
each underwriter (as defined below) established in the UK, which has determined that the Securities are: (i) compatible 
with an end target market of retail investors and investors who meet the criteria of professional clients and eligible 
counterparties, each as defined in Chapter 3 of the FCA Handbook Conduct of Business Sourcebook; and (ii) eligible for 
distribution through all permitted distribution channels (the "UK Target Market Assessment"). 
Notwithstanding the MiFID II Target Market Assessment and the UK Target Market Assessment, distributors should note 
that: the price of the Securities may decline and investors could lose all or part of their investment; the Securities 
offer no guaranteed income and no capital protection; and an investment in the Securities is compatible only with 
investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an 
appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who 
have sufficient resources to be able to bear any losses that may result therefrom. 
The MiFID II Target Market Assessment and the UK Target Market Assessment are without prejudice to any contractual, 
legal or regulatory selling restrictions in relation to the offering of the Securities. 
Furthermore, it is noted that, notwithstanding the MiFID II Target Market Assessment, the underwriters (as defined 
below) established in the EEA will only procure investors who meet the criteria of professional clients and eligible 
counterparties under MiFID II and that, notwithstanding the UK Target Market Assessment, the underwriters established 
in the UK will only procure investors who meet the criteria of professional clients and eligible counterparties under 
Chapter 3 of the FCA Handbook Conduct of Business Sourcebook. For the avoidance of doubt, the MiFID II Target Market 
Assessment and the UK Target Market Assessment do not constitute: (a) in the case of the MiFID II Target Market 
Assessment, an assessment of suitability or appropriateness for the purposes of MiFID II and in the case of the UK 
Target Market Assessment, an assessment of suitability or appropriateness for the purposes of Chapters 9A or 10A 
respectively of the FCA Handbook Conduct of Business Sourcebook; or (b) a recommendation to any investor or group of 
investors to invest in, or purchase, or take any other action whatsoever with respect to the offered Securities. Each 
distributor is responsible for undertaking its own relevant target market assessment in respect of the offered 
Securities and determining appropriate distribution channels. 
This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", 
"assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking 
statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial 
divergence between the actual results, financial situation, development or performance of PolyPeptide Group and those 
explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should 
not rely on forward-looking statements. PolyPeptide Group assumes no responsibility to up-date forward-looking 
statements or to adapt them to future events or developments. 
Except as required by applicable law, PolyPeptide Group has no intention or obligation to update, keep updated or 
revise this publication or any parts thereof following the date hereof. 
None of the underwriters (as defined below) or any of their respective subsidiary undertakings, affiliates or any of 
their respective directors, officers, employees, advisers, agents, alliance partners or any other entity or person 
accepts any responsibility or liability whatsoever for, or makes any representation, warranty or undertaking, express 
or implied, as to the truth, accuracy, completeness or fairness of the information or opinions in this announcement (or 
whether any information has been omitted from the announcement) or any other information relating to the group, its 
subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever 
transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or 
otherwise arising in connection therewith. Accordingly, each of the underwriters and the other foregoing persons 
disclaim, to the fullest extent permitted by applicable law, all and any liability, whether arising in tort or contract 
or that they might otherwise be found to have in respect of this announcement and/or any such statement. 
Each of Credit Suisse AG, Morgan Stanley Europe SE, Merrill Lynch International, Danske Bank A/S, Joh. Berenberg, 
Gossler & Co. KG and Zürcher Kantonalbank (the "underwriters") is acting exclusively for PolyPeptide Group and no one 
else in connection with any transaction referred to in this document. Each of the underwriters will not regard any 
other person as a client and will not be responsible to anyone other than PolyPeptide Group for providing the 
protections afforded to their respective clients nor for the giving of advice in relation to any transaction, matter or 
arrangement referred to herein. 
This publication includes industry and market information based on the PolyPeptide Group's analysis of multiple 
internal and third party sources, including information extracted from market research, governmental and other publicly 
available information, independent industry publications and information and reports prepared by consulting firms 
(which has been produced based on publications comprising industry data, forecasts, market and customer surveys, 
analyst reports, other consultant strategy reports and other information made available to it by third party data 
providers, industry associations, competitors, published accounts, interviews with key market participants/primary 
interviews and virtual field visits it conducted with industry experts and participants, secondary market research and 
internal financial and operational information supplied by, or on behalf of, the Group). Readers should be aware that 
market data and statistics are inherently predictive and speculative and are not necessarily reflective of actual or 
future market conditions. Such statistics are based on market research, which itself is based on sampling and 
subjective judgments by both the researchers and the respondents. In addition, the value of comparisons of statistics 
of different markets is limited by many factors, including that (i) the underlying information is gathered by different 
methods with varying levels of access and information available in different markets and (ii) different assumptions are 
applied in compiling the data. Market studies are frequently based on information and assumptions that may not be exact 
or appropriate and their methodology is by nature forward-looking and speculative. 
Ende der Ad-hoc-Mitteilung 
Sprache:       Deutsch 
Unternehmen:   PolyPeptide Group 
               Dammstrasse 19 
               CH-6300 Zug 
Telefon:       +41 41 723 23 23 
E-Mail:        mediateam@polypeptide.com 
Internet:      www.polypeptide.com 
ISIN:          CH1110760852 
Valorennummer: 111076085 
Börsen:        SIX Swiss Exchange 
EQS News ID:   1193015 
Ende der Mitteilung EQS Group News-Service 

1193015 2021-05-05 CET/CEST


(END) Dow Jones Newswires

May 05, 2021 11:42 ET (15:42 GMT)

Im Artikel erwähnte Wertpapiere
CREDIT SUISSE GROUP AG 0.32%9.39 verzögerte Kurse.-17.89%
DANSKE BANK A/S -0.18%110.2 verzögerte Kurse.9.64%
DJ INDUSTRIAL -0.92%34792.67 verzögerte Kurse.13.83%
MORGAN STANLEY -0.32%96.29 verzögerte Kurse.40.96%
POLYPEPTIDE GROUP AG -0.52%96.5 verzögerte Kurse.0.00%
Alle Nachrichten zu POLYPEPTIDE GROUP AG
25.06.Polypeptide ernennt Christina Del Vecchio zum General Counsel
25.06.EQS-ADHOC : PolyPeptide Group ernennt Christina Del Vecchio zum General Counsel ..
25.06.POLYPEPTIDE : ernennt Christina Del Vecchio zum General Counsel und Mitglied der..
25.06.PolyPeptide Group ernennt Christina Del Vecchio zum General Counsel und Mitgl..
09.06.Polypeptide-Aktien getragen von positiven Analystenstimmen
05.05.Banken üben Mehrzuteilungsoption zu Polypeptide-IPO vollständig aus
05.05.EQS-ADHOC : PolyPeptide Group gibt vollständige -2-
05.05.POLYPEPTIDE : gibt vollständige Ausübung der Mehrzuteilungsoption bekannt
05.05.PolyPeptide Group gibt vollständige Ausübung der Mehrzuteilungsoption bekannt
04.05.POLYPEPTIDE : Investor Rudolf Maag ist Grossaktionär
Weitere Nachrichten
News auf Englisch zu POLYPEPTIDE GROUP AG
25.06.POLYPEPTIDE : appoints Christina Del Vecchio as General Counsel and member of th..
25.06.PolyPeptide Group AG Appoints Christina Del Vecchio as General Counsel and Me..
12.05.Montana Aerospace shares soar on Swiss stock market debut
10.05.POLYPEPTIDE GROUP AG(SWX : PPGN) added to Swiss Performance Index (Price Return)
06.05.GLOBAL MARKETS LIVE : Uber, AB Inbev, PayPal...
06.05.POLYPEPTIDE : Overallotment Option Taken In Full In Swiss IPO
05.05.EQS-ADHOC : PolyPeptide Group announces the -2-
05.05.POLYPEPTIDE : announces the exercise of the full over-allotment option
29.04.PolyPeptide Group AG has completed an IPO in the amount of CHF 737.39136 mill..
22.04.PolyPeptide Group Mulls Non-Organic Growth Opportunities
Weitere Nachrichten auf Englisch
Umsatz 2021 261 Mio 309 Mio -
Nettoergebnis 2021 42,2 Mio 50,0 Mio -
Nettoliquidität 2021 186 Mio 220 Mio -
KGV 2021 63,6x
Dividendenrendite 2021 0,22%
Marktkapitalisierung 3 149 Mio 3 726 Mio -
Marktkap. / Umsatz 2021 11,3x
Marktkap. / Umsatz 2022 9,95x
Mitarbeiterzahl 910
Streubesitz 31,3%
Dauer : Zeitraum :
PolyPeptide Group AG : Chartanalyse PolyPeptide Group AG | MarketScreener
Chartanalyse-Trends POLYPEPTIDE GROUP AG
Durchschnittl. Empfehlung KAUFEN
Anzahl Analysten 5
Letzter Schlusskurs 90,34 €
Mittleres Kursziel 80,79 €
Abstand / Durchschnittliches Kursziel -10,6%
Revisionen zum Gewinn je Aktie
Vorstände und Aufsichtsräte
Raymond de Vre Chief Executive Officer
Jan Fuhr Miller Chief Financial Officer
Peter Wilden Chairman
Daniel Lasanow Director-Global Operations
Patrick Aebischer Vice Chairman
Branche und Wettbewerber
01.01.Wert (M$)
MODERNA, INC.269.97%155 195
LONZA GROUP AG26.48%59 070
CELLTRION, INC.-24.93%31 463
SEAGEN INC.-6.81%28 780